Canadian biopharmaceutical company Medicure, a specialist in the field of cardiovascular drugs, says it has acquired exclusive US rights to Aggrastat injection (tirofiban HCl), a glycoprotein IIb/IIa inhibitor used for the treatment of acute coronary syndrome, from USA-based company MGI Pharma. The drug was originated by Merck & Co, which continues to market the drug outside the USA, and was launched in the region in 1998, with marketing rights subsequently passing to MGI when it acquired Guildford Pharmaceuticals in 2005.
Just a bit of history for those relatively new to MPH. I do remember ,that when this happened , 1 particular poster was very irrate at the aquisition . Thank goodness it occurred as it has been a saviour for the company. I had been holding for sometime before this event and survived the failed MC 1 product trial which saw the stock drop from .80 to .115 in feb of 2008. As time went by ,the price ,from what I recall,fell to 2 or 3 cents.
I've since recouped my investment (thankyou Dr Friesen and staff) and am only holding a minimal number of shares. I will not tender my shares and will see how it plays out to the end. I have faith in the good Dr. that this will not go private and another miracle will occur for other loyal investors to benefit. Good luck.